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Pancreatic cancer is the ﬁfth most common cause of cancer death in the western world and the prognosis for unresectable
disease remains poor. Recent advances in conventional chemotherapy and the development of novel ‘molecular’ treatment
strategies with different toxicity proﬁles warrant investigation as combination treatment strategies. This randomised study in
pancreatic cancer compares marimastat (orally administered matrix metalloproteinase inhibitor) in combination with
gemcitabine to gemcitabine alone. Two hundred and thirty-nine patients with unresectable pancreatic cancer were randomised
to receive gemcitabine (1000 mg m
72) in combination with either marimastat or placebo. The primary end-point was survival.
Objective tumour response and duration of response, time to treatment failure and disease progression, quality of life and
safety were also assessed. There was no signiﬁcant difference in survival between gemcitabine and marimastat and gemcitabine
and placebo (P=0.95 log-rank test). Median survival times were 165.5 and 164 days and 1-year survival was 18% and 17%
respectively. There were no signiﬁcant differences in overall response rates (11 and 16% respectively), progression-free survival
(P=0.68 log-rank test) or time to treatment failure (P=0.70 log-rank test) between the treatment arms. The gemcitabine and
marimastat combination was well tolerated with only 2.5% of patients withdrawn due to presumed marimastat toxicity. Grade
3 or 4 musculoskeletal toxicities were reported in only 4% of the marimastat treated patients, although 59% of marimastat
treated patients reported some musculoskeletal events. The results of this study provide no evidence to support a
combination of marimastat with gemcitabine in patients with advanced pancreatic cancer. The combination of marimastat with
gemcitabine was well tolerated. Further studies of marimastat as a maintenance treatment following a response or stable
disease on gemcitabine may be justiﬁed.
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Pancreatic cancer is the ﬁfth most common cause of cancer death
in the western world. There are an estimated 26000 deaths in the
US and 50000 deaths per year in Europe (excluding the former
USSR) (Fernandez et al, 1994; Wingo et al, 1995). The overall 5
year survival rate (5YSR) for patients with pancreatic cancer ranges
from 51% to less than 5% even in the best prognosis patients and
there has been little improvement in survival in the last 20 years
(Bramhall et al, 1995). The 5YSR for patients with pancreatic
cancer is the lowest reported for any cancer (Ries et al, 1994).
Recent changes in attitude towards pancreatic cancer treatment
have led to the development of novel agents for the treatment of
this disease. Several studies have reported encouraging results with
single chemotherapy agents or combination treatments (Mallinson
et al, 1980; Casper et al, 1994; Palmer et al, 1994; Carmichael et al,
1995; Burris et al, 1997) and gemcitabine has been compared to 5-
ﬂuorouracil (5-FU) in a phase III study in patients with advanced
pancreatic cancer (Burris et al, 1997). The results of this study
suggested that patients receiving gemcitabine had both an
improved survival and patient beneﬁt compared to those patients
receiving 5-FU and these data and data from several other studies
have led to the widespread acceptance of gemcitabine as ﬁrst-line
therapy in patients with advanced pancreatic cancer (Casper et
al, 1994; Carmichael et al, 1995; Rothenberg et al, 1996; Burris et
al, 1997; Storniolo et al, 1999).
The rapid increase in knowledge of the molecular and cellular
biology of malignancy has enabled scientists to accurately target
cellular pathways with synthetic compounds and inhibit these path-
ways for potential therapeutic beneﬁt. Several of these strategies
have been tested in clinical trials in patients with a variety of
tumour types. One such treatment strategy has been the inhibition
of matrix metalloproteinases (MMPs).
The MMPs are proteolytic enzymes that each have different
substrate speciﬁcities within the extracellular matrix and have been
shown to be important in its degradation (Cottam and Rees, 1993).
An imbalance between activated MMP and tissue speciﬁc inhibitors
is believed to lead to extracellular matrix degradation and tumour
invasion. Studies in animal models of malignancy have reported
that MMP inhibitors (MMPIs) can restrict the growth and regional
spread of solid tumours, inhibit metastases and inhibit tumour
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www.bjcancer.comneovascularisation (Brown and Giavazzi, 1995). Expression of
several members of the MMP family is signiﬁcantly greater in
pancreatic cancer than normal pancreas (Sato et al, 1994; Gress
et al, 1995; Bramhall et al, 1996, 1997).
Several broad-spectrum synthetic MMPIs have been developed
and marimastat (British Biotech Pharmaceuticals Ltd., Oxford,
UK) was the ﬁrst in a series of new generation MMPIs with sufﬁ-
cient oral absorption to justify its use in clinical trials. Marimastat
and its predecessor batimastat have been widely tested in a range of
cancer models (Davies et al, 1993; Chivri et al, 1994; Watson et al,
1995, 1999). The principal effect of marimastat is to retard tumour
growth and metastatic spread but it does not display cytotoxic
activity in cell culture and no tumour regression has been observed
in animal models (Chivri et al, 1994; Watson et al, 1995; Zervos et
al, 1997, 1999). The theoretical role of marimastat therefore, would
be as a maintenance therapy with or without concomitant cyto-
toxic therapy, in patients at risk of relapse following ‘curative’
therapy or with minimal or microscopic disease. The activity of
marimastat as a novel agent has ﬁrst been determined in patients
with advanced disease.
A phase II study of marimastat in patients with advanced
pancreatic cancer determined an appropriate dose schedule that
achieved acceptable levels of toxicity. The main toxicity noted with
marimastat was a dose dependent musculoskeletal pain that
responded to drug omission but if treatment persisted could lead
to contractures, particularly of the hand. The same study demon-
strated a surrogate clinical response determined by a decrease in
the tumour antigen CA19-9 production. Both toxicity and tumour
antigen effect appeared to be dose dependent (Nemunaitis et al,
1998; Evans et al, 2001). A pivotal international multi-center
randomised study compared the effect of three different doses of
marimastat with gemcitabine in patients with advanced pancreatic
cancer. The study failed to reach its primary endpoint but did
show a dose-dependent effect of marimastat and reported a 1-year
survival of 19% for patients treated with gemcitabine and 20% for
patients receiving 25 mg b.i.d of marimastat (P=ns) (Bramhall et
al, 2001b). Progression free survival was signiﬁcantly better for
patients treated with gemcitabine (P=0.0001) but this was
predicted based on the mode of action of the two drugs. Explora-
tory analysis of these data suggested that survival in patients treated
with marimastat with non-metastatic pancreatic cancer was signiﬁ-
cantly better than in patients with metastatic disease (P=0.035) but
this was not the case in patients treated with gemcitabine
(P=0.456) (Bramhall et al, 2001b). These data suggest that marima-
stat might be more beneﬁcial in patients with low volume disease
and this was also supported in a placebo-controlled study of mari-
mastat in gastric and gastro-oesophageal cancer (Bramhall et al,
2001a).
The mode of action of marimastat and the toxicity proﬁle deter-
mined from the phase II and III studies suggest that marimastat
might have a role in combination with a cytotoxic agent. Data
from a phase I study indicated that the combination of gemcitabine
and marimastat is well tolerated (unpublished data). This interna-
tional multi-centre randomised study compares the effect of
gemcitabine combined with marimastat against gemcitabine and
placebo on survival, safety, time to disease progression, time to
treatment failure, radiological response and duration of response.
PATIENTS AND METHODS
Patient population
This randomised study included patients with histologically or
cytologically proven adenocarcinoma of the pancreas that was
unresectable on computerised tomographic (CT) or magnetic reso-
nance imaging (MRI). Patients were required to be aged over 18
years and have a Karnofsky performance status (KPS) of at least
60%. Patients had to have adequate bone marrow reserve at study
entry, deﬁned as an absolute granulocyte count of 51500 mm
3,
platelet count of 5100000 ml
71 and haemoglobin 510 gm dL
71.
Adequate baseline hepatic function (deﬁned as bilirubin
52.0 mg dL
71, aspartate transaminase (AST), alanine transami-
nase or alkaline phosphatase 4ﬁve times the upper limit of
normal) and adequate renal function (creatinine 41.5 mg dL
71)
were also required. Any form of previous systemic anti-cancer ther-
apy as a primary intervention for locally advanced or metastatic
disease was disallowed, as was prior exposure to a metalloprotei-
nase inhibitor or gemcitabine. Patients who had received prior
adjuvant or consolidation chemotherapy or radiotherapy and
relapsed within 6 months of ﬁnishing therapy were excluded. Preg-
nant or lactating patients were excluded. Patients who had received
other investigational agents within 4 weeks prior to commencing
the study were excluded. All tumours were staged using the UICC
TNM classiﬁcation and then stage grouped according to the Amer-
ican Joint Committee on Cancer Staging criteria for pancreatic
cancer.
The primary study endpoint was overall survival. Secondary
study endpoints were objective tumour response rate, duration of
response, time to treatment failure, time to disease progression
and quality of life assessment. Safety and tolerability were also
assessed. The study was performed in accordance with the Declara-
tion of Helsinki, approved by Institutional Review Boards and local
regulatory authorities as appropriate and conducted in accordance
with the FDA Guideline on Good Clinical Practice.
Patient assignment
Signed and witnessed informed consent was obtained from each
patient prior to study entry. Patients were assigned to study treat-
ment using a computer generated random code according to the
method of minimisation. This method balanced the treatment
groups on the basis of stage of disease (stage I/II, III or IV),
KPS (60–70% vs 80–100%), gender, disease status (newly diag-
nosed vs recurrent vs recurrent + other treatment), measurable
disease (measurable vs non-measurable) and study centre. Patients
were randomised to receive either 1000 mg m
72 of gemcitabine
hydrochloride by intravenous infusion and marimastat 10 mg
b.i.d or gemcitabine at the same dose and placebo. The marima-
stat/placebo treatment was administered in a double-blinded
fashion.
Treatment
Patients received marimastat or placebo with food. The dose of
marimastat could be reduced if musculoskeletal or other toxicities
developed. If musculoskeletal toxicities were greater than or equal
to National Cancer Institute – Common Toxicity Criteria (NCI
CTC) grade 2 or other toxicity of grade 4 developed, marimastat
was omitted until the symptoms had abated. Patients could then
restart at a 50% dose reduction i.e. once daily instead of twice-daily
administration. If toxicity of the severity described above recurred,
then marimastat again would be omitted until the symptoms had
abated and a further 50% dose reduction would be instituted i.e.
alternate day dosing. If symptoms still persisted then consideration
to withdraw the patient was made. Once a marimastat dose reduc-
tion had been mandated, no escalation to the previous level was
permitted at a later date. Patients were seen on a weekly basis while
receiving gemcitabine and on a monthly basis if receiving marima-
stat/placebo alone and after 28 days following study
discontinuation.
Gemcitabine hydrochloride (Gemzar
1 Eli Lilly and Company,
Indianapolis, USA) was supplied as a lyophilised powder. The drug
was stored and prepared in accordance with the manufacturer’s
instructions. Patients were seen and administered 1000 mg m
72
weekly for the ﬁrst 7 weeks with a rest in week eight and thereafter
1000 mg m
72 weekly for 3 weeks, with a rest in the fourth week. A
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0.5–0.99 ml
71 or a platelet count of 50000–99999 ml
71 and if
the counts were lower then the next dose was omitted. Patients
who could not be treated for 6 weeks due to toxicity would be
withdrawn from the study. Gemcitabine dose was recalculated if
patients experienced a change in weight of 410%.
Patients were not allowed to receive concomitant anti-cancer
therapy.
Statistical analysis
The sample size of 200 (100 per group) was calculated to enable
detection of absolute differences in survival at 18 months of
13.5% between those patients treated with gemcitabine and mari-
mastat and those treated with gemcitabine and placebo, with a
power of 580% and using a signiﬁcance level of 0.05 (log-rank
test). These calculations were based on 90% mortality at study
censure with gemcitabine and placebo and a mortality of 76.5%
in the gemcitabine and marimastat treated group. The treatment
groups were compared on an intention-to-treat basis using
Kaplan-Meier survival curves. In all survival analyses, patients
who were lost to follow up were censored at last known date alive.
Proportions were tested using the w
2 test. Patient beneﬁt data was
tested using the Wilcoxon rank-sum test, and repeated measures
analysis was applied to the quality of life data.
Efﬁcacy and safety evaluation
The primary efﬁcacy endpoint in this study was survival. All survi-
val analyses were performed on an intention-to-treat basis and
included all patients minimised. Treatment continued until death,
disease progression or drug toxicity that warranted removal from
the study. Once patients progressed, they were removed from the
study and received best supportive care as determined by the inves-
tigator. If a patient was removed from the study for any reason,
they were seen 1 month later and thereafter every 2 months until
death.
Secondary endpoints were objective tumour response rate, dura-
tion of response, time to treatment failure, time to disease
progression, quality of life assessment and safety and tolerability.
Objective tumour response rate was deﬁned according to the
WHO criteria for response. Consecutive chest X-ray, CT or MRI
scans were reviewed by the same radiologist in the patients centre
and response was deﬁned as complete, partial, stable disease or
progressive disease. CT or MRI scans were performed within the
14 days prior to day 0 and then every 2 months for the ﬁrst 6
months and thereafter every 3 months and at early termination.
Complete response was deﬁned as disappearance of all known
disease for a minimum of 4 weeks. Partial response was deﬁned
as a 550% decrease in the sum of the products of the largest
perpendicular diameters of all measurable lesions for a minimum
of 4 weeks. Progressive disease was deﬁned as a 525% increase
in the sum of the products of the largest perpendicular diameters
of all measurable lesions from the study nadir, the appearance of
new lesions or death. Patients who did not meet the criteria for
complete response; partial response or progressive disease and
who remained on study for at least 4 weeks were classiﬁed as
having stable disease. Duration of response was deﬁned in patients
with a partial response as the time of initiation of therapy to the
date of objective disease progression and in those patients with a
complete response as the time from the date of onset of the
response to the date of objective disease progression. Patients dying
prior to documented progressive disease were considered to have
experienced progressive disease at death. Time to treatment failure
was deﬁned as the time from randomisation to permanent discon-
tinuation of the combination regimen for any reason, including
death, disease progression, unacceptable toxicity, investigator deci-
sion or patient decision. Quality of life assessment included an
assessment of pain (Memorial Pain Assessment card – MPAC),
level of analgesic required, KPS, surgical interventions to alleviate
cancer related symptoms, patient weight changes and formal qual-
ity of life assessment (using FACT-Pa questionnaire).
Patients were evaluated by weekly examination of vital signs,
weight and full blood counts and 4-weekly history, clinical exami-
nation and biochemical proﬁle. KPS, FACT-Pa quality of life
assessment, pain assessment and analgesic rating were performed
at baseline and every 4 weeks thereafter. All signs, symptoms and
laboratory abnormalities were assessed using the NCI CTC criteria
for toxicities. In addition, a speciﬁc rating for grading musculoske-
letal toxicity was developed for use with marimastat (Bramhall et
al, 2001b). Grade 1 musculoskeletal toxicity was deﬁned as aches
and pains with no restriction of activity. Grade 2 was deﬁned as
having pain causing restriction of activity. Grade 3 was deﬁned
as having pain and the presence of nodules or clinically inﬂamed
joints or tendons and grade 4 was pain and the presence of a
contracture.
RESULTS
Two hundred and thirty-nine patients were recruited from 18
North American (114 patients) and 19 European (125 patients)
sites between September 1997 and April 1998. Of the 239 patients
randomised 120 were randomised to receive gemcitabine and mari-
mastat (GM) and 119 to receive gemcitabine and placebo (GP).
Forty-four patients received chemotherapy post study (21 in the
GM and 23 in the GP groups). All patients are included in this
intention-to-treat analysis, but two patients randomised to GM
and two randomised to GP treatment did not receive any study
drug and so are excluded from the safety analysis but not the efﬁ-
cacy analysis. The patient demographics and key prognostic factors
were similar between the two treatment groups (Table 1).
Final analysis of the study was performed when 90% mortality
had occurred in the GM treatment group (August 1999). Differ-
ences between individual treatment groups were determined
using the log-rank test. Analysis revealed no difference in overall
survival between the two treatment arms (P=0.95, hazard ratio
(HR) 0.99, 95% conﬁdence intervals (CI) 0.76–1.30). There was
no difference in median survival, GM (165.5 days) compared to
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Table 1 Patient demographic data by treatment group
Gemcitabine and Gemcitabine and
Marimastat Placebo
Number 120 119
Patient sex
Male 69 71
Female 51 48
Median age in years (range) 62 (32–83) 62 (37–85)
Median weight (range) (kg) 70 (37–112) 68 (38–148)
Extent of disease at study entry (%)
A1 8 1 5
B1 2 1 2
C7 0 7 3
Disease status (%)
Newly diagnosed 89 92
Recurrent 8 5
Recurrent+adjuvant therapy 3 3
Presence of liver metatases (%) 59 62
Karnofsky performance status
560 1 0
60–70 32 31
80–100 86 86
Unknown 1 2
A = Conﬁned to the pancreas (stage I & II); B = Non-metastatic disease but invading
outside pancreas (stage III); C = Metastatic disease (stage IV)
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group and 17% for the GP group.
There was no signiﬁcant difference in response rates between the
two treatment arms (Table 2), however, there was a trend in favour
of placebo in the duration of response with a median of 118 days
in the GM arm (n=14) and 258 days (n=15) in the GP arm
(P=0.07 log-rank test). The median time to treatment failure
favoured the GM treated patients, 107 days compared to 89 days
in the GP treated patients (P=0.70) (Figure 2). Analysis of progres-
sion-free survival however, revealed no difference between the GM
arm (92.5 days) and the GP arm (96 days) (P=0.68, HR 0.95, 95%
CI 0.73–1.23).
Exploratory analyses of overall survival in patients with meta-
static (stage IV) and non-metastatic (stage I/II/III) disease
revealed no difference between the GM and GP treatment arms.
The median survival time in patients without metastases and trea-
ted with GM (n=36) was 266 days and in those treated with GP
(n=32) was 290 days (P=0.67, HR 1.13, 95% CI 0.66–1.94). The
median survival time in patients with metastatic disease and treated
with GM (n=84) was 138.5 days and in those treated with GP
(n=87) was 140 days (P=0.59, HR 0.92, 95% CI 0.67–1.25).
Further exploratory analysis of the subset of patients with a good
KPS (80–100) and with disease conﬁned to the pancreas gland
(stage I/II) revealed an improved survival in those patients treated
with GM (n=14, median survival time=451 days) when compared
with those patients treated with GP (n=16, median survival
time=266.5 days) (P=0.33, HR 1.54, 95% CI 0.65–3.66).
There were no statistically signiﬁcant differences between GP
and GM treated arms with respect to pain, mood, analgesic use,
KPS or weight as assessed by change from baseline standardised
areas under the curve (AUCs) up to 2 months (Bailey et al,
1998). There was however, a difference in quality of life assessed
using FACT-Pa. The median change from baseline standardised
AUC to 2 months was 0.88 for GP treated patients and 71 for
GM treated patients (P=0.048, Wilcoxon rank sum test), indicating
an improved quality of life for GP treated patients.
Safety
Compliance and tolerance of therapy was good with patients
receiving a median of 106 days (range 0–654 days) treatment with
marimastat in the GM arm and 85 days (range 0–619 days) treat-
ment with placebo in the GP arm. Gemcitabine treatment
continued for a median of 11 doses (range 0–56 doses) and 10
doses (range 0–56 doses) in the GM and GP arms respectively.
Overall 2.5% (three out of 118) of patients treated with marimastat
were withdrawn due to adverse events compared to 3.4% (four out
of 117) in the placebo arm; 0.8% (one out of 118) of GM patients
and 1.7% (two out of 117) GP patients were withdrawn due to
possible gemcitabine related toxicity. One of the marimastat
patients was withdrawn due to musculoskeletal toxicity. The
reasons for withdrawal due to possibly drug related events related
to gemcitabine were rash, vasculitis and anaemia.
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Figure 1 Primary mortality analysis (intention-to-treat).
Table 2 Rate of response
Gemcitabine and Gemcitabine and
marimastat placebo
Response N % N %
Complete 1 1 0 0
Partial 10 10 14 16
Stable 48 50 49 56
Progressive 38 39 25 28
Total 97 100 88 100
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Placebo (n=119)
Marimastat (n=120)
P=0.70
median = 89 days
median = 107 days
Figure 2 Time to treatment failure.
Table 3 NCI CTC grades 3 out of 4 for laboratory and adverse event
based parameters (% incidence ranked by frequency)
Gemcitabine and Gemcitabine and
Marimastat Placebo
NCI criteria (laboratory)
Any event 50 52
Lymphocytes 36 34
Bilirubin 16 16
Alkaline phosphatase 3 12
Granulocytes/bands 3 9
Hyperglycaemia 13 8
Haemoglobin 3 7
NCI criteria (adverse event)
Any event 59 62
Neurocortical 17 19
Vomiting 6 14
Infection 11 12
Nausea 7 12
Pulmonary 14 9
Neuromotor 14 7
Table 4 Musculoskeletal events by severity (% of patients)
Event Treatment Mild Moderate Severe
Arthralgia GM 16 13 5
GP 13 7 2
Joint stiffness GM 3 2 1
GP 2 0 0
Myalgia GM 13 4 0
GP 8 5 0
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no deaths on study attributable to treatment. All deaths were
considered to be secondary to disease progression. The NCI-CTC
grades were assigned as a multiple of the normal range irrespective
of causality (Table 3), therefore factors related to the underlying
disease such as liver metastases may have an inﬂuence. The overall
incidence of grade 3 or 4 adverse events was similar between the
two treatment arms. As expected, gemcitabine exerted a myelosup-
pressive effect on all haematological parameters with no signiﬁcant
difference being seen between either treatment arm. Severe muscu-
losketal toxicities were reported with both marimastat and placebo,
although marginally more commonly in the GM treatment arm
(Table 4). Musculoskeletal adverse events were reported in 59%
of GM treated patients and 44% of GP treated patients (P=0.031,
w
2 test).
GM patients (47.5%) and GP patients (38.6%) had their mari-
mastat/placebo dosage reduced or required a drug holiday
because of musculosketal toxicity. The median time to a musculos-
keletal event was shorter in the GM arm (77 days) compared with
the GP arm (139 days) (P=0.053, log-rank test). The mean number
of gemcitabine dose reductions was 2.61 in the GM patients and
2.19 in the GP patients.
DISCUSSION
The prognosis in patients with pancreatic cancer is poor. Bramhall
et al (1995) reported an overall 5YSR in a series of 13560 patients
with pancreatic cancer of 50.2% with only 2.6% undergoing resec-
tion (5YSR of 5.5%) (Bramhall et al, 1995). Gudjonsson (1987)
reported similar results in an overview of the published literature
and an analysis of patients from his own institution. Traditionally
therefore, most clinicians have viewed pancreatic cancer in a nihi-
listic manner and have been only prepared to offer supportive care
(Douglass, 1987). Until recently there had been little data to
contradict this approach in patients with advanced disease, with
the majority of studies failing to report any survival advantage in
patients treated with conventional chemo-radiotherapy (Bramhall
and Neoptolemos, 1997). The recent introduction of gemcitabine
however, has lead to the widespread acceptance of this drug as ﬁrst
line treatment for patients with advanced pancreatic cancer and
attention has now turned to the combination of gemcitabine with
other therapies (van Moorsel et al, 1997; Colucci et al, 1998;
Cardenal et al, 1999; Cascinu et al, 1999; Hidalgo et al, 1999).
There has been a recent increase in the development of novel
classes of agents speciﬁcally directed towards molecular ‘defects’
in malignant disease and the MMPIs were the ﬁrst class of such
agents to enter clinical trials (Bramhall et al, 2001a,b). The tumour
biology of pancreatic tumours made patients with pancreatic
cancer an obvious choice to test MMP inhibition as a treatment
strategy and phase II and III studies of marimastat have now been
completed and reported (Bramhall et al, 2001b; Evans et al, 2001).
The differing mode of action and toxicity proﬁle of gemcitabine
and marimastat make the combination of these agents an obvious
therapeutic strategy to investigate.
This study was powered to detect an absolute difference in
survival between the GM and GP treatment arms. The primary
mortality analysis did not reveal a signiﬁcant difference in survival
between the treatment groups.
In the randomised study of gemcitabine vs 5-FU, reported by
Burris et al (1997) survival of the gemcitabine patients was very
similar to the survival seen in both treatment arms of this study
and in the gemcitabine and 25 mg b.i.d treated arms of the
previously mentioned phase III study of marimastat vs gemcitabine
(Bramhall et al, 2001b). The median survival time for patients
receiving gemcitabine in the study by Burris was 169 days and
132 days for those receiving 5-FU, the median survival time for
patients receiving gemcitabine in the study by Bramhall was 167
days and for those patients receiving marimastat 25 mg b.i.d was
125 days. In this study the median survival time for the GM
arm was 165.5 days and 164 days in the GP arm. The 1-year survi-
vals were 18 and 2% for gemcitabine and 5-FU (Burris et al, 1997),
19 and 20% for gemcitabine and marimastat (Bramhall et al,
2001b) and in this study 18 and 17% for GM and GP respectively.
The three studies had similar patient populations but patients in
the Burris study had to be symptomatic. There is, however a large
imbalance in performance status between the three studies. In the
Burris study 31% of patients had a performance of 70% or more,
whereas patients in the study by Bramhall had had a better perfor-
mance status with 75% of patients having a KPS of more than 70%
and in this study 72% had a KPS of more than 70%. The efﬁcacy
results of the Burris study are not therefore really comparable with
the other two studies.
There is little support for therapeutic beneﬁt of marimastat in
combination with gemcitabine in the current study. Overall survival
was no different for patients treated with gemcitabine in combination
with marimastat compared to gemcitabine in combination with
placebo. There was a trend towards a survival difference in explora-
tory sub-group analysis when patients with disease conﬁned to the
pancreas and with a good performance status were treated with
GM (although the numbers in this analysis were very small) and these
data are consistent with the ﬁndings of the studies of marimastat in
advanced pancreatic and gastro-oesophageal cancer which both
suggested that marimastat was more efﬁcacious in patients with
low volume disease (Bramhall et al, 2001a,b).
Marimastat was generally well tolerated and appears to have an
acceptable toxicity proﬁle in combination with gemcitabine. This
study conﬁrms the ﬁndings from the two previous randomised
studies of marimastat that marimastat treatment is associated with
musculoskeletal pain. Although this can become severe if patients
continue to take marimastat in the presence of symptoms, it does
appear to reverse on cessation of treatment, in most cases within
1–2 weeks. Further evidence for this can be seen by the reduction
in severe musculoskeletal complications seen in this study (5%)
compared with the two previous studies (7% with 10 mg b.i.d
and 12.8% with 25 mg b.i.d). The side effects of marimastat can
be understood and managed by the patients themselves, unlike
some of the more severe side effects associated with cytotoxic treat-
ments.
The choice of marimastat dose in this study might have been
sub-optimal when the results of the previous randomised study
of marimastat in pancreatic cancer are considered. This study
was designed and commenced prior to analysis of the results of
the comparative study between gemcitabine and marimastat. In this
study there was a dose dependent effect of marimastat with the
dose of 25 mg b.i.d comparing favourably with gemcitabine in
pancreatic cancer (Bramhall et al, 2001b). In this study marimastat
dosing was 10 mg b.i.d and could be considered sub-optimal,
however even in sub-group analysis there was very little indication
of synergy between marimastat and gemcitabine. In conclusion the
combination of gemcitabine and a MMPI can be safely delivered to
patients with pancreatic cancer but there appears little evidence to
support further study of this combination. However, further
studies of the use of marimastat as maintenance treatment follow-
ing a response or stable disease on gemcitabine may be justiﬁed on
the basis of the recent ﬁndings in gastric cancer. This study found
that when marimastat was compared with placebo in advanced
gastric cancer prolonged survival was found to be most marked
in patients who had previously received chemotherapy and in those
patients without metastatic disease (Bramhall et al, 2001b).
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